GlassScriptPhysician profile
Seth T Billiodeaux
NPI 1841492196
$4,475.25
in general payments reported to CMS, 2019-2025
23 companies · $1,817 in 2025
The $1,817 reported for 2025 was more than what 78% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $126 · 2021: $314 · 2022: $425 · 2023: $794 · 2024: $742 · 2025: $1,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,467 · Travel and Lodging: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,466.74 |
| Travel and Lodging | $885.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,588.74 | 2022-2025 | Botox, Qulipta, Ubrelvy |
| Spinal Simplicity, LLC | $995.76 | 2025 | Ha Minuteman G3-R |
| Medtronic, INC. | $422.29 | 2023-2025 | Inceptiv, Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Boston Scientific Corporation | $243.01 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Allergan, INC. | $239.14 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $203.48 | 2023-2025 | Iovera, Exparel, Zilretta |
| Stryker Corporation | $115.88 | 2023 | Avaflex, Multigen 2, Ivas |
| Nevro Corp. | $94.70 | 2019-2024 | Senza |
| Novartis Pharmaceuticals Corporation | $85.87 | 2019-2020 | |
| Hydrocision, INC. | $71.49 | 2024 | Tenjet |
| Lundbeck LLC | $63.85 | 2022-2024 | Vyepti |
| Abbott Laboratories | $60.95 | 2022-2023 | Proclaim |
| Biohaven Pharmaceuticals, INC. | $60.02 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $50.65 | 2019-2021 | |
| Amgen INC. | $38.64 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $22.94 | 2024 | Collagenase Santyl |
| Portola Pharmaceuticals, LLC | $18.70 | 2019 | |
| Integra Lifesciences Corporation | $18.67 | 2019 | |
| Pacira Therapeutics, INC. | $17.87 | 2019 | |
| Fidia Pharma USA INC. | $17.79 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.18 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $16.05 | 2024 | |
| Bioventus LLC | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Billiodeaux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.